What Zynerba’s Flop Means For CBD Therapies And GW Pharmaceuticals

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) lost more than 58 percent of their value Monday morning after the company reported disappointing results from its phase 2 STAR 1 clinical trial

read more

Source: What Zynerba’s Flop Means For CBD Therapies And GW Pharmaceuticals